Denemek ALTIN - Özgür

FDA Cites Failure to Report GLP-1 Risks

The Wall Street Journal

March 11, 2026

Novo Nordisk said it is working quickly to respond to the FDA's request.

- BY ELIAS SCHISGALL

Novo Nordisk received a warning from the Food and Drug Administration for failing to report serious suspected side effects in patients who took the company's GLP-1 treatments.

Bu hikaye The Wall Street Journal dergisinin March 11, 2026 baskısından alınmıştır.

Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.

Zaten abone misiniz? Oturum aç